Featured Publications
Pulmonary Complications of Immunotherapy
Bade BC, Possick JD. Pulmonary Complications of Immunotherapy. Clinics In Chest Medicine 2020, 41: 295-305. PMID: 32402364, DOI: 10.1016/j.ccm.2020.02.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLung cancerImmune checkpoint inhibitor therapyImmune-related adverse eventsTreatment-limiting complicationsCheckpoint inhibitor therapyFurther prospective investigationMetastatic lung cancerFavorable safety profileTreatment of patientsPulmonary complicationsAdverse eventsClinical vigilanceInhibitor therapySignificant morbiditySafety profileProspective InvestigationCurrent guidelinesMortality riskImmunotherapyComplicationsPatientsCancerPneumonitisMorbidityChemotherapyPulmonary Toxicities from Checkpoint Immunotherapy for Malignancy
Possick JD. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. Clinics In Chest Medicine 2017, 38: 223-232. PMID: 28477635, DOI: 10.1016/j.ccm.2016.12.012.ChaptersPulmonary Complications of Lung Cancer Treatment
McAvoy K, Possick J. Pulmonary Complications of Lung Cancer Treatment. Respiratory Medicine 2023, 229-254. DOI: 10.1007/978-3-031-38412-7_11.ChaptersPulmonary complicationsTreatment-related risk factorsNonspecific respiratory symptomsLife-saving therapyLung cancer treatmentLung cancer therapyUnderstanding of patientsRespiratory symptomsRadiographic findingsAttendant complicationsDiagnostic challengeRisk factorsTreatment paradigmRadiation therapyTraditional chemotherapyComplicationsAccurate diagnosisAreas of uncertaintyCancer treatmentTherapyCancer therapyDisease responsePatientsImmunotherapyChemotherapy
2023
Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome
Singh I, Leitner B, Wang Y, Zhang H, Joseph P, Lutchmansingh D, Gulati M, Possick J, Damsky W, Hwa J, Heerdt P, Chun H. Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome. Pulmonary Circulation 2023, 13: e12220. PMID: 37091121, PMCID: PMC10113513, DOI: 10.1002/pul2.12220.Peer-Reviewed Original ResearchInvasive cardiopulmonary exercise testPASC patientsPost-acute sequelaeAcute sequelaeInfection syndromeUnexplained exertional intoleranceCardiopulmonary exercise testSystemic oxygen deliveryPersistent inflammatory stateVenous blood plasmaExertional intolerancePeak exerciseEndothelial dysfunctionHemodynamic profileInflammatory stateExercise testFibrotic processPathophysiological hallmarkAberrant protein expressionExpression of proteinsOxygen deliveryOxygen extractionProteomic profilingPatientsPhysiologic responses
2018
Should Physicians New to a Case Counsel Patients and Their Families to Change Course at the End of Life?
Honiden S, Possick J. Should Physicians New to a Case Counsel Patients and Their Families to Change Course at the End of Life? The AMA Journal Of Ethic 2018, 20: e699-707. PMID: 30118419, DOI: 10.1001/amajethics.2018.699.Commentaries, Editorials and LettersConceptsGoals of careLife care optionsPhysician practice variationEnd of lifeAdvanced malignanciesCounsel patientsCritical illnessOncology patientsNew cancer therapiesCare discussionsIndividual patientsPractice variationCare plansComfort measuresPhysician objectionPatientsCare optionsPhysiciansCancer therapyClinical momentumPotential benefitsPrognosisMalignancyTherapyIllness
2016
Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.
Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.Peer-Reviewed Original Research